Tuesday, 16 April, 2024
HomeMedico-LegalDu Pont loses appeal over cancer toxic chemical ruling

Du Pont loses appeal over cancer toxic chemical ruling

A federal appeals court has upheld a $40m verdict for a cancer survivor who sued EI Du Pont de Nemours and Co after years of exposure to a toxic chemical that it manufactured.

Reuters reports that the 6th US Circuit Court of Appeals on Monday said DuPont could not challenge the verdict, which relied on a finding in related cases that PFOA, a chemical discharged by DuPont into public waterways, was linked to the man's cancer.

“The key concept applicable here is that DuPont’s conduct impacted the plaintiffs in virtually identical ways: contamination of their water supplies with a carcinogen,” wrote Circuit Judge Jane Stranch for the panel.

The decision upheld a jury verdict awarded to Travis Abbott in 2020.

PFOA is among a class of chemicals known as per- and polyfluoroalkyl substances (PFAS) that have been used in non-stick products such as Teflon, and are associated with certain cancers. They are referred to as “forever chemicals” because they don’t easily break down in the human body or nature.

Abbott sued in 2017, claiming prolonged exposure to PFOA in his drinking water caused him to have testicular cancer twice.

DuPont has said Abbott’s level of exposure was unlikely to have caused his cancer.

A jury awarded Abbott $40m after a 2020 trial in Ohio federal court, finding that PFOA was likely the cause of his illness.

Abbott's case against DuPont is one of thousands in multi-district litigation consolidated in Ohio. The lawsuits claim that the company poisoned drinking water by discharging the chemical PFOA into waterways from its plant in Parkersburg, West Virginia.

 

Reuters – dupont-loses-challenge-over-cancer-victims-40-mln-verdict-pfas-cas

 

More from Medical Brief archives

us-states-crack-down-on-toxic-forever-chemicals/

forever-chemicals-detected-in-all-umbilical-cord-blood-in-40-studies/

pfas-exposure-associated-with-early-menopause

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.